NO20016198L - Orale farmasöytiske sammensetninger som inneholder taxaner og fremgangsmåter for anvendelse av samme i behandling - Google Patents
Orale farmasöytiske sammensetninger som inneholder taxaner og fremgangsmåter for anvendelse av samme i behandlingInfo
- Publication number
- NO20016198L NO20016198L NO20016198A NO20016198A NO20016198L NO 20016198 L NO20016198 L NO 20016198L NO 20016198 A NO20016198 A NO 20016198A NO 20016198 A NO20016198 A NO 20016198A NO 20016198 L NO20016198 L NO 20016198L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- methods
- same
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US707195P | 1995-10-26 | 1995-10-26 | |
US08/608,776 US5968972A (en) | 1995-10-26 | 1996-02-29 | Method for increasing the oral bioactivity of pharmaceutical agents |
US08/733,142 US6245805B1 (en) | 1995-10-26 | 1996-10-16 | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
US86351397A | 1997-05-27 | 1997-05-27 | |
PCT/US1999/013821 WO2000078247A1 (en) | 1995-10-26 | 1999-06-18 | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20016198D0 NO20016198D0 (no) | 2001-12-18 |
NO20016198L true NO20016198L (no) | 2002-02-05 |
Family
ID=47631112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20016198A NO20016198L (no) | 1995-10-26 | 2001-12-18 | Orale farmasöytiske sammensetninger som inneholder taxaner og fremgangsmåter for anvendelse av samme i behandling |
Country Status (16)
Country | Link |
---|---|
US (2) | US6964946B1 (uk) |
EP (1) | EP1221908A4 (uk) |
JP (1) | JP2003502349A (uk) |
CN (1) | CN1361677A (uk) |
AU (1) | AU774060B2 (uk) |
BR (1) | BR9917403A (uk) |
CA (1) | CA2371924A1 (uk) |
CZ (1) | CZ20014589A3 (uk) |
HU (1) | HUP0300836A3 (uk) |
MX (1) | MXPA01013116A (uk) |
NO (1) | NO20016198L (uk) |
NZ (1) | NZ516279A (uk) |
PL (1) | PL196267B1 (uk) |
SK (1) | SK18782001A3 (uk) |
UA (1) | UA77646C2 (uk) |
WO (1) | WO2000078247A1 (uk) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6828346B2 (en) * | 1999-10-25 | 2004-12-07 | Supergen, Inc. | Methods for administration of paclitaxel |
US6136846A (en) * | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
BR0015149A (pt) * | 1999-10-27 | 2002-10-29 | Baker Norton Pharma | Método e composições para administração de taxanos oralmente a pacientes humanos |
US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
EP1365759A2 (en) * | 2001-01-18 | 2003-12-03 | PHARMACIA & UPJOHN COMPANY | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
AU2002357012A1 (en) * | 2001-11-27 | 2003-06-10 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
JP2006501134A (ja) * | 2001-12-20 | 2006-01-12 | ブリストル−マイヤーズ スクイブ カンパニー | 高い生物学的利用能を有する、経口活性タキサン誘導体の医薬組成物 |
EP1498143A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
EP1510206A1 (en) * | 2003-08-29 | 2005-03-02 | Novagali Pharma SA | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
CN1853728A (zh) * | 2005-04-19 | 2006-11-01 | 上海天博生物科技有限公司 | 一种改善药物或营养物口服吸收的方法、配方及其应用 |
AR054215A1 (es) * | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
CZ300677B6 (cs) * | 2006-05-03 | 2009-07-15 | I.Q.A., A. S. | Farmaceutický prostredek s obsahem docetaxelu, urcený pro prípravu infúzního roztoku, zpusob jeho výroby a použití |
WO2008058366A1 (en) * | 2006-09-28 | 2008-05-22 | Université de Montréal | Oil-in-water emulsions, methods of use thereof, methods of preparation thereof and kits thereof |
AU2008269179A1 (en) * | 2007-06-22 | 2008-12-31 | Scidose Llc | Solubilized formulation of docetaxel without Tween 80 |
KR101478779B1 (ko) * | 2007-11-22 | 2015-01-05 | 에스케이케미칼주식회사 | 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법 |
KR101502533B1 (ko) * | 2007-11-22 | 2015-03-13 | 에스케이케미칼주식회사 | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 |
ES2344674B1 (es) * | 2008-08-07 | 2011-06-29 | Gp Pharm, S.A. | Composicion farmaceutica inyectable de taxanos. |
US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
TWI471321B (zh) * | 2009-06-08 | 2015-02-01 | Abbott Gmbh & Co Kg | Bcl-2族群抑制劑之口服醫藥劑型 |
TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
TW201113266A (en) * | 2009-09-02 | 2011-04-16 | Ziopharm Oncology Inc | Pharmaceutical formulations for indibulin |
US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
US8476310B2 (en) | 2009-10-19 | 2013-07-02 | Scidose Llc | Docetaxel formulations with lipoic acid |
US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
MX2012007325A (es) * | 2009-12-22 | 2012-07-20 | Abbott Lab | Capsula de abt-263. |
EP2566474B1 (en) | 2010-05-03 | 2017-11-15 | Teikoku Pharma USA, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
TWI838700B (zh) * | 2015-09-30 | 2024-04-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
FR3042498A1 (fr) * | 2015-10-14 | 2017-04-21 | Naturex | Nouveau solvant d'extraction et/ou de solubilisation organique, procede d'extraction mettant en oeuvre ledit solvant, et extraits issus dudit procede |
CN113559277B (zh) * | 2018-01-11 | 2023-11-17 | 比卡生物科技(广州)有限公司 | 一种注射用卡巴他赛组合物及其制备方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
FR2678833B1 (fr) | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
CA2149150C (en) | 1992-11-27 | 2000-08-01 | David R. Carver | Injectable taxol composition with improved stability |
FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
TW406020B (en) | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
US5610173A (en) | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
US5567592A (en) | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
US5565478A (en) | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
US5616330A (en) | 1994-07-19 | 1997-04-01 | Hemagen/Pfc | Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same |
US5681846A (en) | 1995-03-17 | 1997-10-28 | Board Of Regents, The University Of Texas System | Extended stability formulations for paclitaxel |
US5665386A (en) | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5716928A (en) | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
GB9514878D0 (en) | 1995-07-20 | 1995-09-20 | Danbiosyst Uk | Vitamin E as a solubilizer for drugs contained in lipid vehicles |
US6245805B1 (en) | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
CN1209059A (zh) | 1995-12-21 | 1999-02-24 | 基因实验室技术有限公司 | 紫杉烷类组合物及方法 |
US5877205A (en) | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
PL337064A1 (en) * | 1997-05-27 | 2000-07-31 | Baker Norton Pharma | Method of and compositions for orally administering taxanes to human beings |
BE1011216A3 (fr) | 1997-06-13 | 1999-06-01 | Thissen En Abrege L T B Lab | Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition. |
BR9811058A (pt) | 1997-07-29 | 2000-09-05 | Upjohn Co | Formulação auto-emulsificante para compostos lipofìlicos |
GB9718903D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
IL131217A0 (en) | 1998-03-10 | 2001-01-28 | Napro Biotherapeutics Inc | Novel methods and compositions for delivery of taxanes |
IL138767A0 (en) | 1998-04-01 | 2001-10-31 | Rtp Pharma Inc | Anticancer compositions |
-
1998
- 1998-04-06 US US09/055,818 patent/US6964946B1/en not_active Expired - Fee Related
-
1999
- 1999-06-18 EP EP99930408A patent/EP1221908A4/en not_active Withdrawn
- 1999-06-18 NZ NZ516279A patent/NZ516279A/en unknown
- 1999-06-18 MX MXPA01013116A patent/MXPA01013116A/es active IP Right Grant
- 1999-06-18 CA CA002371924A patent/CA2371924A1/en not_active Abandoned
- 1999-06-18 UA UA2001128795A patent/UA77646C2/uk unknown
- 1999-06-18 AU AU46955/99A patent/AU774060B2/en not_active Ceased
- 1999-06-18 CZ CZ20014589A patent/CZ20014589A3/cs unknown
- 1999-06-18 HU HU0300836A patent/HUP0300836A3/hu unknown
- 1999-06-18 BR BR9917403-0A patent/BR9917403A/pt not_active Application Discontinuation
- 1999-06-18 CN CN99816838A patent/CN1361677A/zh active Pending
- 1999-06-18 SK SK1878-2001A patent/SK18782001A3/sk unknown
- 1999-06-18 JP JP2001504316A patent/JP2003502349A/ja active Pending
- 1999-06-18 PL PL359924A patent/PL196267B1/pl not_active IP Right Cessation
- 1999-06-18 WO PCT/US1999/013821 patent/WO2000078247A1/en not_active Application Discontinuation
-
2001
- 2001-12-18 NO NO20016198A patent/NO20016198L/no not_active Application Discontinuation
-
2005
- 2005-06-24 US US11/165,896 patent/US20050267201A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU4695599A (en) | 2001-01-09 |
CZ20014589A3 (cs) | 2002-07-17 |
NZ516279A (en) | 2004-06-25 |
WO2000078247A1 (en) | 2000-12-28 |
CN1361677A (zh) | 2002-07-31 |
JP2003502349A (ja) | 2003-01-21 |
AU774060B2 (en) | 2004-06-17 |
HUP0300836A2 (hu) | 2003-08-28 |
US6964946B1 (en) | 2005-11-15 |
CA2371924A1 (en) | 2000-12-28 |
HUP0300836A3 (en) | 2005-11-28 |
NO20016198D0 (no) | 2001-12-18 |
PL359924A1 (en) | 2004-09-06 |
EP1221908A4 (en) | 2002-10-09 |
PL196267B1 (pl) | 2007-12-31 |
BR9917403A (pt) | 2002-07-09 |
UA77646C2 (en) | 2007-01-15 |
SK18782001A3 (sk) | 2002-09-10 |
US20050267201A1 (en) | 2005-12-01 |
MXPA01013116A (es) | 2002-06-04 |
EP1221908A1 (en) | 2002-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20016198L (no) | Orale farmasöytiske sammensetninger som inneholder taxaner og fremgangsmåter for anvendelse av samme i behandling | |
DK1093815T3 (da) | Oral 2-methyl-thieno-benzodiazepinformulering | |
DE69618587D1 (de) | Chinazoline und pharmazeutische zusammensetzungen | |
CY2005007I1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη | |
IS4360A (is) | Lyfjablanda í skammtaformi til munninntöku | |
NO20021172D0 (no) | Farmasöytisk sammensetning | |
NO982311D0 (no) | Sammensetninger og fremgangsmÕter for forhindring og behandling av oral mukositt | |
EE9800028A (et) | Iprotroopiumsoolad, neid sisaldavad ravimkompositsioonid ja nende kasutamine | |
DE59712959D1 (de) | Orale pharmazeutische zubereitung enthaltend ibandronat | |
BR9607851B1 (pt) | combinaÇço e formulaÇço farmacÊutica. | |
NO308294B1 (no) | Dimetyl-3(aryl-but-3-enyl)-aminforbindelse som farmasøytiske forbindelser og anvendelse av disse | |
NO975987D0 (no) | 4-Fenylaminotiazol-derivater, fremgangsmåte for fremstilling av disse og farmasöytiske blandinger inneholdende nevnte derivater | |
NO976128D0 (no) | Forbindelser og farmasöytiske blandinger som inneholder dem | |
ATE186541T1 (de) | Quillajasaponin-zusatz und diesen enthaltende impfstoffformulierung | |
HUP9900071A3 (en) | Tribenzimidazoles useful as topoisomerase i inhibitors, pharmaceutical compositions containing them and their use | |
EE9800400A (et) | Diklofenaaki sisaldavad farmatseutilised kompositsioonid | |
NO20001717D0 (no) | Serotonin-inneholdende formulering for oral administrering og anvendelse av samme | |
NO306114B1 (no) | Substituerte 4-fenyltiazolderivater og farmasöytiske blandinger som inneholder dem | |
LV11727A (lv) | Farmaceitiska kompozicija | |
ITMI932014A0 (it) | Composizioni farmaceutiche orali effervescenti contenenti estrone | |
FI973280A (fi) | Farmaseuttinen koostumus | |
FI973230A0 (fi) | Uusi farmaseuttinen formulaatio | |
DE69509621D1 (de) | Diarylheptanoidderivat und diese enthaltende pharmazeutische Zusammensetzung | |
BR9605777A (pt) | Composição farmacêutica | |
DE69528372D1 (de) | Orale behandlung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |